Merck Patent Gesellschaft MIT

Helga Kahlert

Wolf-Dieter Müller

Albrecht Bufe

Helmut Fiebig

Wolf-Meinhard Becker

Gabriele Schramm

Hans-Thomas Stüwe

Oliver Cromwell

Lothar Jäger

The invention relates to modified recombinant allergen mutants which can be obtained from recombinant allergens which are derived from allergens which can be obtained by extraction from natural raw materials such as pollen of the speciesWhile these modified recombinant allergens stimulate lymphocytes from patients who are allergic to pollent to proliferate and synthesize cytokines, they exhibit a markedly diminished ability to bind to the IgE antibodies which are present in the serum of the T lymphocyte donors and to grass pollen allergen-specific IgEs and can therefore be used for a specific, made-to-release allergy therapy.

Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same

Growing community of inventors

Darmstadt, Germany

Helga Kahlert